1. Home
  2. PCRX vs QDEL Comparison

PCRX vs QDEL Comparison

Compare PCRX & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$25.41

Market Cap

999.0M

Sector

Health Care

ML Signal

N/A

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

N/A

Current Price

$12.37

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
QDEL
Founded
2006
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
999.0M
1.2B
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
PCRX
QDEL
Price
$25.41
$12.37
Analyst Decision
Strong Buy
Hold
Analyst Count
4
4
Target Price
$30.25
$28.25
AVG Volume (30 Days)
642.3K
1.3M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
107.44
45.35
EPS
0.19
N/A
Revenue
$541,533,000.00
$2,730,200,000.00
Revenue This Year
$6.78
$3.51
Revenue Next Year
$8.54
$3.86
P/E Ratio
$131.68
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$9.92
52 Week High
$27.66
$35.58

Technical Indicators

Market Signals
Indicator
PCRX
QDEL
Relative Strength Index (RSI) 44.73 29.07
Support Level $24.61 $10.39
Resistance Level $26.94 $12.85
Average True Range (ATR) 1.00 1.08
MACD -0.25 -0.41
Stochastic Oscillator 18.84 13.20

Price Performance

Historical Comparison
PCRX
QDEL

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

Share on Social Networks: